Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 250

1.

Implementing managed entry agreements in practice: The Dutch reality check.

Makady A, van Veelen A, de Boer A, Hillege H, Klungel OH, Goettsch W.

Health Policy. 2018 Sep 28. pii: S0168-8510(18)30529-3. doi: 10.1016/j.healthpol.2018.09.016. [Epub ahead of print]

PMID:
30316540
2.

Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study.

Bakhriansyah M, Souverein PC, Klungel OH, de Boer A, Blom MT, Tan HL.

Europace. 2018 Aug 10. doi: 10.1093/europace/euy180. [Epub ahead of print]

PMID:
30107407
3.

Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate.

Althunian TA, de Boer A, Groenwold RHH, Klungel OH.

J Clin Epidemiol. 2018 Dec;104:15-23. doi: 10.1016/j.jclinepi.2018.07.004. Epub 2018 Aug 25.

PMID:
30009941
4.

Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study.

Bloem LT, Mantel-Teeuwisse AK, Leufkens HGM, De Bruin ML, Klungel OH, Hoekman J.

Clin Pharmacol Ther. 2018 Jul 3. doi: 10.1002/cpt.1169. [Epub ahead of print]

PMID:
29969839
5.

Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use.

Marees AT, Hammerschlag AR, Bastarache L, de Kluiver H, Vorspan F, van den Brink W, Smit DJ, Denys D, Gamazon ER, Li-Gao R, Breetvelt EJ, de Groot MCH, Galesloot TE, Vermeulen SH, Poppelaars JL, Souverein PC, Keeman R, de Mutsert R, Noordam R, Rosendaal FR, Stringa N, Mook-Kanamori DO, Vaartjes I, Kiemeney LA, den Heijer M, van Schoor NM, Klungel OH, Maitland-Van der Zee AH, Schmidt MK, Polderman TJC, van der Leij AR, Posthuma D, Derks EM.

Drug Alcohol Depend. 2018 Jul 1;188:94-101. doi: 10.1016/j.drugalcdep.2018.03.026. Epub 2018 Apr 25.

6.

Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink.

de Jong HJI, Cohen Tervaert JW, Lalmohamed A, de Vries F, Vandebriel RJ, van Loveren H, Klungel OH, van Staa TP.

PLoS One. 2018 Feb 23;13(2):e0193297. doi: 10.1371/journal.pone.0193297. eCollection 2018.

7.

Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study.

van Dalem J, Brouwers MCGJ, Stehouwer CDA, Krings A, Klungel OH, Driessen JHM, de Vries F, Burden AM.

Diabetes Obes Metab. 2018 Apr;20(4):1056-1060. doi: 10.1111/dom.13168. Epub 2017 Dec 27.

8.

Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Kievit W, Klungel OH, Verbeek ALM, Wong DR, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Bouvy ML, de Jong DJ.

Eur J Gastroenterol Hepatol. 2018 Feb;30(2):167-173. doi: 10.1097/MEG.0000000000001025.

9.

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.

Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Klungel OH, Verbeek ALM, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Wong DR, de Jong DJ.

Aliment Pharmacol Ther. 2017 Nov;46(10):953-963. doi: 10.1111/apt.14323. Epub 2017 Sep 15.

10.

Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting.

Bezin J, Klungel OH, Lassalle R, Dureau-Pournin C, Moore N, Pariente A.

Clin Pharmacol Ther. 2018 Jun;103(6):1038-1046. doi: 10.1002/cpt.864. Epub 2017 Sep 28.

PMID:
28875506
11.

Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.

Wing K, Bhaskaran K, Pealing L, Root A, Smeeth L, van Staa TP, Klungel OH, Reynolds RF, Douglas I.

J Antimicrob Chemother. 2017 Sep 1;72(9):2636-2646. doi: 10.1093/jac/dkx183.

12.

The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase.

Alharbi FF, Kholod AAV, Souverein PC, Meyboom RH, de Groot MCH, de Boer A, Klungel OH.

Fundam Clin Pharmacol. 2017 Dec;31(6):676-684. doi: 10.1111/fcp.12313. Epub 2017 Sep 5.

PMID:
28767167
13.

Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study.

De Jong HJI, van Staa TP, Lalmohamed A, de Vries F, Vandebriel RJ, Van Loveren H, Klungel OH, Cohen Tervaert JW.

Ann Rheum Dis. 2017 Oct;76(10):1723-1730. doi: 10.1136/annrheumdis-2016-210936. Epub 2017 Jul 6.

PMID:
28684558
14.

The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: A case-control study.

Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL.

Br J Clin Pharmacol. 2017 Nov;83(11):2541-2548. doi: 10.1111/bcp.13356. Epub 2017 Aug 16.

15.

More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.

Broekman MMTJ, Coenen MJH, van Marrewijk CJ, Wanten GJA, Wong DR, Verbeek ALM, Klungel OH, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, de Jong DJ; TOPIC Recruitment Team.

Inflamm Bowel Dis. 2017 Oct;23(10):1873-1881. doi: 10.1097/MIB.0000000000001163.

16.

Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.

Bakhriansyah M, Souverein PC, de Boer A, Klungel OH.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1141-1148. doi: 10.1002/pds.4183. Epub 2017 Mar 31.

17.

Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study.

Alharbi FF, Souverein PC, de Groot MC, Maitland-van der Zee AH, de Boer A, Klungel OH.

J Hum Hypertens. 2017 Aug;31(8):537-544. doi: 10.1038/jhh.2017.1. Epub 2017 Mar 23.

PMID:
28332511
18.

Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review.

Althunian TA, de Boer A, Klungel OH, Insani WN, Groenwold RH.

Trials. 2017 Mar 7;18(1):107. doi: 10.1186/s13063-017-1859-x. Review.

19.

Defining the noninferiority margin and analysing noninferiority: An overview.

Althunian TA, de Boer A, Groenwold RHH, Klungel OH.

Br J Clin Pharmacol. 2017 Aug;83(8):1636-1642. doi: 10.1111/bcp.13280. Epub 2017 Apr 6.

20.

A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.

Ankarfeldt MZ, Adalsteinsson E, Groenwold RH, Ali MS, Klungel OH.

Clin Epidemiol. 2017 Jan 23;9:41-51. doi: 10.2147/CLEP.S121991. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center